As part of Erlanger’s expansion of its cancer program, Erlanger Health System has entered into an official agreement with University Oncology and Hematology Associates to provide infusion services in the practice’s offices located in the Erlanger Medical Mall. This means Erlanger oncology patients can receive chemotherapy services in the Infusion Center on the Erlanger Baroness Campus, as well as the new infusion location, which will operate under the name UT Erlanger Oncology and Hematology.
With the addition of UT Erlanger Oncology and Hematology’s new infusion location in the Medical Mall offices of University Oncology, Erlanger has consolidated its capabilities to treat cancer patients at the Baroness Campus. “We will offer patients the same quality chemotherapy treatments and compassionate care in our practice as they have received in the Erlanger Infusion Center,” said Dr. Larry Schlabach of University Oncology, who is also Erlanger’s medical director of Oncology Services. Dr. Schlabach’s partners at University Oncology are Dr. John McCravey and Dr. Robert Graham.
“Our professional services agreement with University Oncology is another step forward in enhancing our cancer program,” said Kevin M. Spiegel, FACHE, Erlanger president and CEO. “I am pleased that we will be working closely with Dr. Schlabach and his team as Erlanger presses forward to offer the most comprehensive cancer services in the region. Cancer patients in our community will benefit as Erlanger and University Oncology join forces in providing infusion services.”
One of the region’s most well-respected oncologists, Dr. Schlabach is also chief of Oncology for the UT College of Medicine Chattanooga, based at Erlanger. In this position, Dr. Schlabach not only serves in a teaching role for other physicians, but also conducts cancer research that permits many of his patients to participate in national clinical trials and receive treatments that might not otherwise be widely available.
The Erlanger Infusion Center provides patients with a variety of outpatient care procedures and treatment options, including chemotherapy, bone marrow biopsies, blood transfusions and growth factors.
Cancer patients also have access to the treatment options at Erlanger, including the region’s only CyberKnife, the world’s only robotic radiation system. CyberKnife targets tumors almost anywhere in the body, and patients can complete therapy in as few as five visits. Radiation oncology services at Erlanger also include linear accelerators, CT simulator and three-dimensional planning computers for treating even the most complex cases.
Last month, Erlanger received approval from the State of Tennessee to acquire a PET scanner as an additional diagnostic tool for oncology patients.